Scholars@Duke

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

Publication ,  Journal Article
Zelenetz, AD; Gordon, LI; Abramson, JS; Advani, RH; Andreadis, B; Bartlett, NL; Budde, LE; Caimi, PF; Chang, JE; Christian, B; DeVos, S; Hu, B ...
Published in: J Natl Compr Canc Netw
November 2023
Published version (DOI) Link to item

Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

Duke Scholars

Christopher Ryan Kelsey
Author Christopher Ryan Kelsey Radiation Oncology

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2023.0057

EISSN

1540-1413

Publication Date

November 2023

Volume

21

Issue

11

Start / End Page

1118 / 1131

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • Oncology & Carcinogenesis
  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular
  • Immunotherapy, Adoptive
  • Humans
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, B., Bartlett, N. L., … Sundar, H. (2023). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw, 21(11), 1118–1131. https://doi.org/10.6004/jnccn.2023.0057
Zelenetz, Andrew D., Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L Elizabeth Budde, et al. “NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.” J Natl Compr Canc Netw 21, no. 11 (November 2023): 1118–31. https://doi.org/10.6004/jnccn.2023.0057.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023 Nov;21(11):1118–31.
Zelenetz, Andrew D., et al. “NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.” J Natl Compr Canc Netw, vol. 21, no. 11, Nov. 2023, pp. 1118–31. Pubmed, doi:10.6004/jnccn.2023.0057.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023 Nov;21(11):1118–1131.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2023.0057

EISSN

1540-1413

Publication Date

November 2023

Volume

21

Issue

11

Start / End Page

1118 / 1131

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • Oncology & Carcinogenesis
  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular
  • Immunotherapy, Adoptive
  • Humans
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis